Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network

Kelsie Pearson a,*, Nicole Mayer-Hamblett a,b,c, Christopher H. Goss a,d, George Z. Rettsch-Bogart e, Jill M. VanDalsen e, Patricia Burks f, Daniel Rosenbluth g, John Paul Clancy h, Amy Hoffman a, David P. Nichols a,b

a Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children’s Hospital, Seattle, WA, United States
b Department of Pediatrics, University of Washington, Seattle, WA, United States
c Department of Biostatistics, University of Washington, Seattle, WA, United States
d Department of Medicine, University of Washington, Seattle, WA, United States
e Division of Pediatric Pulmonology, University of North Carolina, Chapel Hill, NC, United States
f Cystic Fibrosis Foundation, Bethesda, MD, United States
h Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St Louis, Missouri, United States

A R T I C L E   I N F O

Article history:
Received 28 October 2020
Revised 4 December 2020
Accepted 7 December 2020
Available online 15 December 2020

Keywords:
Cystic fibrosis
Clinical research
Coronavirus
SARS-CoV-2

A B S T R A C T

The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) global pandemic significantly impacted CF clinical research within the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDN). A Research Electronic Data Capture (REDCap) survey was developed and sent to network sites to monitor and understand the impact on research teams, ongoing and anticipated clinical research, and specific clinical and research procedures. Key findings indicated an early impact on participant enrollment, research team stability, and procedures such as spirometry and sputum induction. These trends steadily improved over the months as research activities began to recover across the TDN. While SARS-CoV-2 created a significant challenge it also highlights new opportunities to expand CF research with greater focus on data collection outside of research centers and increased access for remote participation.

© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) global pandemic significantly impacted the conduct of CF clinical research worldwide [1-3], in addition to disrupting many other aspects of daily life [4]. Underlying pulmonary diseases like cystic fibrosis (CF) are seen as risk factors for severe illness from SARS-CoV-2, resulting in heightened awareness of a need to minimize exposure to this virus [5]. Similarly, most CF clinical trials involve aerosol generating procedures (e.g. spirometry), which have been particularly scrutinized due to potential risk of aerosolization and transmission to research staff [6] and other subjects.

In an effort to accurately monitor the evolving and transformative impact of SARS-CoV-2 on the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDN), a US-based CF clinical trial network comprised of 91 clinical research sites, the CFF TDN Coordinating Center (TDNCC) launched a series of surveys between April 2020 and July 2020 (n = 6 surveys). The survey was drafted by CF Foundation and TDNCC Leadership with input from the TDN Research Coordinator Advisory Group. The survey was tested in Research Electronic Data Capture (REDCap) by senior Research Coordinators (RCs) and their input was incorporated. The survey, administered using REDCap, was sent bi-weekly to the Primary Research Coordinator contact at all TDN sites to understand the local impact on research team stability, ongoing and anticipated clinical research, and specific clinical and research procedures. Sites were asked to respond within 3 days and a reminder was sent the morning of the deadline.

Key findings are presented in Fig. 1 and summarized below. Results are presented in percentages as the number of responses to each survey varied over the months (April n = 116, 100% response rate (91/91 sites), May n = 108, 99% response rate (90/91 sites), June n = 108, 98% response rate (89/91 sites), July n = 102, 95% response rate (86/91 sites)). Sites were again asked about enrollment capabilities in September (n = 98, 90% response rate (82/91 sites)). Some sites reported separate responses from their pediatric and adult institutions.

https://doi.org/10.1016/j.jcf.2020.12.007
1569-1993/© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

* Corresponding author.
E-mail address: kelsie.pearson@seattlechildrens.org (K. Pearson).
1. Research team stability

Survey results indicate that the work of RCs and Regulatory Coordinators (RegCs) was heavily affected by SARS-CoV-2. Roughly 75% were required to work-from-home in the months of April and May and nearly 20% were laid off or were working reduced hours because of study conduct interruption in first months. These percentages improved in the following months, with only 45% of RCs and RegCs restricted to home by July and 8% laid off or working reduced hours, as clinical research activities began to recover across the Network.

2. Ongoing and upcoming clinical research

As expected, enrollment was significantly affected in the early months of SARS-CoV-2 with only 15% of sites able to enroll in observational studies, 5% in early phase interventional trials (i.e. phase 1 or 2), and 6% in later phase 3/4 studies. This steadily improved over the summer months with enrollment capability in observational studies increasing to 75%, phase 1/2 trials to 60%, and phase 3/4 to 70%. Despite the significant impacts, institutions and site teams adapted by allowing remote monitoring (97% of sites by July), remote electronic medical record (EMR) access (78%), telemedicine in lieu of in-person visits (91%), and source documents to be taken home (24%) in accordance with data protection policy. This flexibility in standard practices assuredly reduced missing data for participants actively enrolled in studies while likely improving safety monitoring.

3. Clinical and research procedures

Potentially aerosol-generating procedures like spirometry and sputum induction were the most restricted by limitations to research conduct at study sites. Only 27% of sites were able to conduct spirometry in July 2020. However, this paralleled a dramatic increase in the number of sites able to conduct home spirometry for clinical care (20% in April and 75% in July). Some study sponsors provided home spirometers to participating sites and the CF Foundation purchased and distributed several thousand devices to CFF Accredited Care Centers in support of both clinical care and ongoing academic research trials.

Sites also faced restrictions in performing sputum induction with only 19% of sites reporting the ability to perform the procedure by July. Similar to the nimble pivot to home spirometry, sites implemented collection of sputum specimens at home with shipment to local or centralized laboratories. Home sputum collection was available at 34% sites in July, an increase from just 14% in April.

4. Next steps

To continue monitoring the dynamic impact of SARS-CoV-2 on the TDN, a streamlined Smartsheet form was implemented in August 2020 to continue to collect a limited number of key data, which will allow us to monitor both the heterogeneity and commonality of limitations to research conduct over the coming months. As of September, enrollment was resuming at most sites with 90% able to enroll in observational and phase 3/4 studies and 75% in phase 1/2 studies. Additionally, 90% of sites were able to perform in-person spirometry and 50% could perform sputum induction. Combined with the adaptations described above, this indicates that research capacity and activity were returning toward a modified pre-pandemic state, although this remains heterogeneous depending on geographic and institutional considerations. As we transition into the winter months marked with a significant rise of SARS-CoV-2 in many parts of the country, it remains imperative that we continue collecting survey data. This effort paired with others across the globe [7] with allow us to monitor and report out on the impact of SARS-CoV-2 on clinical trials networks as well as the health and well-being of people with CF.

The longitudinal survey results reported here proved essential in the TDN Coordinating Center’s ability to monitor and support sites over the first several months of the SARS-CoV-2 pandemic. Additionally, a subset of results was shared with industry sponsors to better inform their decisions for ongoing and upcoming trials. Overall, while SARS-CoV-2 created a significant barrier to clinical trial activity in the TDN, it also fostered resilience and innovation. Study sites and sponsors rose to the challenge to keep research going in new and creative ways and to ensure that people with CF enrolled in clinical trials remained safe with minimal interruptions to study drug access or key safety monitoring.

The pandemic also highlights new opportunities to expand CF research with greater focus on data collection outside of research centers and increased access for remote participation. Technologies (e.g. home spirometry, electronic patient-reported outcomes, ePROs) and logistical operations (e.g. temperature-controlled ship-
5. Author contributions

All authors drafted the manuscript or revised it critically for important intellectual content. All authors approved the final version of the manuscript.

6. Funding source

This work was supported by the Cystic Fibrosis Foundation (CFF). NMH, CHG, and DPN were also supported by National Institutes of Health (NIH) grants P30 DK 089507. CHG is also supported by the following federal awards: UM1HL119073, UL1TR000423, R01FD003704 and R01FD006848.

Declaration of Competing Interest

NMH has received grant funding from the Cystic Fibrosis Foundation (CFF) and National Institutes of Health (NIH). CHG reports grant funding from CFF, European Commission, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources, Gilead Sciences, Novartis, NIH, Food and Drug Administration, Boehringer Ingelheim, Vertex Pharmaceuticals. None of the work presented in this short communication was influenced by the funding sources reported by CHG. KP, GZRB, JMVD, PB, DR, JPC, AH, and DPN have nothing to disclose related to this work.

Acknowledgements

We would like to thank Jing Xie, Statistical Clinical Data Management Programmer, at the TDN Coordinating Center for her expertise in programming the survey in REDCap. We also want to acknowledge the hard work and contributions of the Research Coordinators who filled out the bi-weekly surveys.

References

[1] Upadhyaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Impact of COVID-19 on oncology clinical trials. Nat Rev Drug Discov 2020;19:376-7.
[2] Desai S, Manjaly P, Lee KJ, Li SJ, Manjaly C, Mostaghi A. The impact of COVID-19 on dermatology clinical trials. J Invest Dermatol 2020.
[3] van Koningsbruggen-Rietschel S, Dunlevy F, Bultheel V, Downey DG, Dupont L. SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network. Eur Respir J 2020;56.
[4] Cosgriff R, Ahern S, Bell SC, Brownlee K, Burgel PR, Byrnes C, Corvol H, Cheng SY, Elbert A, Faro A, Goss CH, Gulmans V, Marshall BC, McKone E, Middleton PG, Ruseckaite R, Stephenson AI, Carr SB. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros 2020;19:355-8.
[5] Prevention CDCa. People with Certain Medical Conditions : 2020.
[6] Pasnick S, Carlos W.G., Dela Cruz C.S., Gross J.E., Garrison G., Jamil S. SARS-CoV-2 Transmission and the Risk of Aerosol Generating Procedures. 2020 Jun 30. Available from: https://www.thoracic.org/patients/patient-resources/resources/aerosol-generating-procedures-and-risk-of-covid-19-transmission.pdf.
[7] McClennaghan E, Cosgriff R, Brownlee K, Ahern S, Burgel PR, Byrnes GA, Colombo C, Corvol H, Cheng SY, Danese G, Elbert A, Faro A, Goss CH, Gulmans V, Gutierrez H, de Monestrol I, Jung A, Justus LN, Kashirskaya N, Marshall BC, McKone E, Middleton PG, Mondejar-Lopez P, Pastor-Vivero MD, Padoan R, Rizvi S, Ruseckaite R, Salvatore M, Stephenson A, Filho L, Melo J, Zampoli M, Carr SB. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. J Cyst Fibros 2020.